Oncodesign Precision Medicine (OPM) is a leading biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers. Their mission is to bring innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis evolution, with the patient at the center of their approach. With a diverse portfolio of technologies, molecules, and therapeutic targets, OPM has proven its ability to discover active molecules for use against resistant and advanced cancers.

They have developed an innovative platform for selecting new therapeutic targets based on patient data and artificial intelligence (AI). OPM's cutting-edge Nanocyclix® technology has yielded two candidate drugs that are expected to enter the clinical phase in 2022, one in partnership with the Servier group and another for treating chronic immune-mediated inflammatory diseases. With a strong foundation in precision medicine since 1995, OPM combines expertise in Pharmimage technology and theranostics to develop new products that effectively target metastatic cells.

Their solid values of solidarity, ingenuity, vitality, rationality, and integrity form the basis of their company culture and reputation. As of 2022, OPM has completed an IPO, has a team of 25 highly qualified employees, and boasts three innovative technologies, six ongoing partnerships, and three molecules scheduled for clinical trials from 2023. Overall, OPM is dedicated to advancing the field of precision medicine and providing innovative solutions for patients with resistant and advanced cancers